The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
COSTEM 2022 | Advantages of bispecific antibodies over CAR-T therapy in LBCL
Marion Subklewe, MD, Ludwig-Maximilians-University of Munich, Munich, Germany, comments on the development of novel bispecific antibodies (bsAbs) for large B-cell lymphoma (LBCL). BsAbs have demonstrated encouraging efficacy and toxicity profiles in multiple clinical trials, culminating in the pending approval of epcoritamab and glofitamab. Compared to CAR-T therapies, bsAbs have favorable safety profiles and have consequently the potential to be in first-line combination therapies. This interview took place at the 7th Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM) in Berlin, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
